Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: RSV Immunization
Interventions: RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 12 Months
Enrollment: 2,226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more

Conditions: Aging
Interventions: Sham, Therapeutic Plasma Exchange, IVIG; Device · Drug
Lead sponsor: Dobri Kiprov; Industry
Eligibility: 50 Years to 95 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Mill Valley, California

Conditions: Obstetrical Complications, Hemorrhage, Labor and Delivery
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 12
States / cities: Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more

Conditions: Diabetes in Pregnancy, Gestational Diabetes, Texting Interventions
Interventions: Text Message Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Critical Illness
Interventions: Psychological Support Based on Positive Suggestions; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ischemic Stroke
Interventions: Thermogard XP3, Recanalization only; Device · Procedure
Lead sponsor: ZOLL Circulation, Inc., USA; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Marietta, Georgia • Honolulu, Hawaii • Chicago, Illinois + 4 more

Conditions: Psoriasis
Interventions: adalimumab, MTX, placebo adalimumab, placebo MTX; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Cervical Cancer, Human Papillomavirus Infection
Interventions: Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Allo-SCT Patients, Adult Allo-SCT Survivor
Interventions: web-based patient education, questionnaire; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorder, Autism
Interventions: L1-79; Drug
Lead sponsor: Yamo Pharmaceuticals LLC; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • Orange, California • San Rafael, California + 5 more

Conditions: Anxiety, Relapse, Substance Addiction
Interventions: Coreg; Drug
Lead sponsor: Aaron J. Janowsky; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Smoking
Interventions: Smoking status as a routine vital sign; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Major Depressive Disorder
Interventions: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 60
States / cities: Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more

Conditions: Eyelid Laceration
Interventions: Tissue Adhesive skin closure, Absorbable suture skin closure, Non-absorbable suture skin closure; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Melanoma
Interventions: Vemurafenib, Dacarbazine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 24
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Chandler, Arizona • Oviedo, Florida • Nampa, Idaho + 7 more

Conditions: Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions: TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: Labour Pain
Interventions: Bupivacaine and Fentanyl (for CSE), Bupivacaine and Fentanyl (for traditional epidural); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions: Ethyl Eicosapentaenoic Acid, OmegaBrite; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cytomegalovirus Infections, HIV Infections, Hypocalcemia
Interventions: Magnesium sulfate, Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Type 2 Diabetes Mellitus, Overweight, Obesity
Interventions: Low carbohydrate, ketogenic diet, Low glycemic index, reduced calorie diet; Behavioral
Lead sponsor: Robert C. Atkins Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Intubation Complication
Interventions: Etomidate, Ketamine; Drug
Lead sponsor: South East Area Health Education Center, Wilmington, NC; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Diabetic Foot, Ulcer Foot
Interventions: Human split thickness skin allograft, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing; Other
Lead sponsor: Professional Education and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • O'Fallon, Illinois • Youngstown, Ohio + 2 more

Conditions: Facial Rosacea
Interventions: Soolantra® Ivermectin cream 1%, Ivermectin cream 1%, Placebo for Ivermectin cream 1%; Drug
Lead sponsor: Zydus Worldwide DMCC; Industry
Eligibility: 18 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Brandon, Florida • Fort Lauderdale, Florida • Miami, Florida + 7 more

Search by objective public record fields.

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy

Psychological Support Based on Positive Suggestions (PSBPS) on Mental Health Morbidity and Cognitive Function

REperfusion With Cooling in CerebraL Acute IscheMia II

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement

Web-based Patient Education Program to Manage Side Effects of Allogeneic Stem Cell Transplant

A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

"The Evaluation of Stimulant Withdrawal"

Checking Smoking Status as a Routine Vital Sign: A Cluster-Randomized Trial of Its Effect on Cessation Counseling

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Cosmetic Outcome Study of Lid Laceration Repair With Suture Versus Tissue Adhesive

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Safety Study of TPI-287 to Treat CBS and PSP

Combined Spinal-Epidural Versus Traditional Labor Epidural

Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial

Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

Lifestyle Modification for Obesity-Related Type 2 Diabetes

Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea